Switch to the original Schedule Online view

Community Schedule

Enter at least 4 characters

0 matches for: 'influenza' in the Therapeutic Groups

3 results showing for: 'influenza'

Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine

[Xpharm]
  • Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-Ag U polio virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe
    • Brand Fully subsidised brand. Infanrix-hexa
    • Pharmacode2459396
    • Subsidy $0.00
    • Measure / Qty per 10

Funded for patients meeting any of the following criteria:

  1. Up to four doses for children up to and under the age of 10 for primary immunisation; or

  2. An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or

  3. Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Haemophilus influenzae type B vaccine

[Xpharm]
  • Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml
    • Brand Fully subsidised brand. Hiberix
    • Pharmacode2087758
    • Subsidy $0.00
    • Measure / Qty per 1

One dose for patients meeting any of the following:

  1. For primary vaccination in children; or

  2. An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or

  3. For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

  • Inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) [Xpharm]
    • Brand Fully subsidised brand. Afluria Quad Junior (2022 formulation)
    • Pharmacode2631989
    • Subsidy $11.00
    • Measure / Qty per 1
    1. INFLUENZA VACCINE – child aged 6 months to 35 months

      is available each year for patients aged 6 months to 35 months who meet the following criteria, as set by Pharmac:

      1. have any of the following cardiovascular diseases

        1. ischaemic heart disease, or

        2. congestive heart failure, or

        3. rheumatic heart disease, or

        4. congenital heart disease, or

        5. cerebo-vascular disease; or

      2. have either of the following chronic respiratory diseases:

        1. asthma, if on a regular preventative therapy, or

        2. other chronic respiratory disease with impaired lung function; or

      3. have diabetes; or

      4. have chronic renal disease; or

      5. have any cancer, excluding basal and squamous skin cancers if not invasive; or

      6. have any of the following other conditions:

        1. autoimmune disease, or

        2. immune suppression or immune deficiency, or

        3. HIV, or

        4. transplant recipients, or

        5. neuromuscular and CNS diseases/disorders, or

        6. haemoglobinopathies, or

        7. on long term aspirin, or

        8. have a cochlear implant, or

        9. errors of metabolism at risk of major metabolic decompensation, or

        10. pre and post splenectomy, or

        11. down syndrome, or

      7. have been hospitalised for respiratory illness or have a history of significant respiratory illness;

      Unless meeting the criteria set out above, the following conditions are excluded from funding:

      1. asthma not requiring regular preventative therapy,

      2. hypertension and/or dyslipidaemia without evidence of end-organ disease.

    2. Doctors are the only Contractors entitled to claim payment for the supply of influenza vaccine inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine) to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

     

     

     

     

     

     

     

     

  • Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) - Only on a prescription - No patient co-payment payable
    • Brand Fully subsidised brand. Afluria Quad (2022 formulation)
    • Pharmacode2631970
    • Subsidy $110.00
    • Measure / Qty per 10
    1. INFLUENZA VACCINE – people 3 years and over

      is available each year for patients aged 3 years and over who meet the following criteria, as set by Pharmac:

      1. all people 65 years of age and over; or

      2. People 55 to 64 years of age (inclusive) and is Māori or any Pacific ethnicity; or

      3. people under 65 years of age who:

        1. have any of the following cardiovascular diseases:

          1. ischaemic heart disease, or

          2. congestive heart failure, or

          3. rheumatic heart disease, or

          4. congenital heart disease, or

          5. cerebo-vascular disease; or

        2. have either of the following chronic respiratory diseases:

          1. asthma, if on a regular preventative therapy, or

          2. other chronic respiratory disease with impaired lung function; or

        3. have diabetes; or

        4. have chronic renal disease; or

        5. have any cancer, excluding basal and squamous skin cancers if not invasive; or

        6. have any of the following other conditions:

          1. autoimmune disease, or

          2. immune suppression or immune deficiency, or

          3. HIV, or

          4. transplant recipients, or

          5. neuromuscular and CNS diseases/disorders, or

          6. haemoglobinopathies, or

          7. are children on long term aspirin, or

          8. have a cochlear implant, or

          9. errors of metabolism at risk of major metabolic decompensation, or

          10. pre and post splenectomy, or

          11. down syndrome, or

        7. are pregnant; or

      4. children 3 and 4 years of age (inclusive) who have been hospitalised for respiratory illness or have a history of significant respiratory illness; or

      5. people under 65 years of age who:

        1. have any of the following serious mental health conditions:

          1. schizophrenia, or

          2. major depressive disorder, or

          3. bipolar disorder, or

          4. schizoaffective disorder, or

        2. are currently accessing secondary or tertiary mental health and addiction services; or

      6. children 3 to 12 years of age (inclusive), from 1 July 2022 to 31 December 2022;

      Unless meeting the criteria set out above, the following conditions are excluded from funding:

      1. asthma not requiring regular preventative therapy,

      2. hypertension and/or dyslipidaemia without evidence of end-organ disease.

    2. Contractors will be entitled to claim payment for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with Health NZ for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

    3. Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

  • Rectangle page icon symoblising a PDF. PDF
  • A tick icon. Fully subsidised
  • An oval with the number 29 in it. Unapproved medicine under Section 29
  • An asterisk symbol. 3 or 6 months should be dispensed at once
  • Two duplicate pages icon. Click to copy
  • A triangle symbol. Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.
  • OP Original pack
  • B Bolded Pharmacode means that the product is to be delisted soon
  • Sole Subsidised Supply